Asia Pacific Prediabetes Market Size & Outlook, 2023-2030
Asia Pacific prediabetes market, 2018-2030 (US$M)
Related Markets
Asia Pacific prediabetes market highlights
- The Asia Pacific prediabetes market generated a revenue of USD 26.7 million in 2023.
- The market is expected to grow at a CAGR of 7.6% from 2024 to 2030.
- In terms of segment, diguanide was the largest revenue generating drug class in 2023.
- Diguanide is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 26.7 million |
| Market revenue in 2030 | USD 44.5 million |
| Growth rate | 7.6% (CAGR from 2023 to 2030) |
| Largest segment | Diguanide |
| Fastest growing segment | Diguanide |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diguanide, Thiazolidinediones, Glucagon-like peptide-1 agonists (GLP-1), SGLT2 inhibitors , DPP-4 inhibitors, Other Drug Classes |
| Key market players worldwide | Novo Nordisk A/S ADR, Resverlogix Corp, AstraZeneca PLC, Bristol-Myers Squibb Co, Valbiotis, Caelus Health, SciMar, Boston Therapeutics, Aphaia |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 13.3% of the global prediabetes market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 44.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Prediabetes Market Scope
Prediabetes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific prediabetes market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to prediabetes market will help companies and investors design strategic landscapes.
Diguanide was the largest segment with a revenue share of 85.02% in 2023. Horizon Databook has segmented the Asia Pacific prediabetes market based on diguanide, thiazolidinediones, glucagon-like peptide-1 agonists (glp-1), sglt2 inhibitors , dpp-4 inhibitors, other drug classes covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Prediabetes Drug Class Outlook (Revenue, USD Million, 2018-2030)
- Diguanide
- Thiazolidinediones
- Glucagon-like peptide-1 agonists (GLP-1)
- SGLT2 inhibitors
- DPP-4 inhibitors
- Other Drug Classes
- Asia Pacific Prediabetes Age Group Outlook (Revenue, USD Million, 2018-2030)
- Children (12-18 years)
- Adults (18-49)
- Elderly (50+)
Reasons to subscribe to Asia Pacific prediabetes market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific prediabetes market databook
-
Our clientele includes a mix of prediabetes market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific prediabetes market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific prediabetes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific prediabetes market size, by country, 2018-2030 (US$M)
Asia Pacific Prediabetes Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
